Top

Clinical Research in Cardiology

Published in:

01-10-2010 | Original Paper

Tacrolimus-eluting carbon-coated stents versus sirolimus-eluting stents for prevention of symptom-driven clinical end points

Authors: J. M. Siller-Matula, I. Tentzeris, B. Vogel, S. Schacherl, R. Jarai, A. Geppert, G. Unger, K. Huber

Published in: Clinical Research in Cardiology | Issue 10/2010

Abstract

Background

Coating of stents has been shown to minimize the interactions between platelets, stent surface and vascular response following stent implantation. The aim of our study was to compare the tacrolimus-eluting carbon-coated JANUS^® stent with sirolimus-eluting CYPHER^® stent for the prevention of symptom-driven clinical end points in a real world clinical setting.

Methods

This prospective registry with a follow-up period of 24 months was conducted in 90 consecutive patients undergoing coronary artery stenting receiving CYPHER^® (n = 48) or JANUS^® (n = 42) stents. The primary end point was a composite of death from cardiovascular causes, nonfatal myocardial infarction and target vessel revascularisation, and the secondary end point was clinically driven in-stent restenosis.

Results

The primary combined endpoint occurred in 38% of patients (n = 16) in the JANUS^® group compared to 10% (n = 5) in the CYPHER^® group. The relative risk increase of the composite end point was therefore 63% higher in patients receiving JANUS^® stents compared to the CYPHER^® stents (crude HR = 1.63, 95% CI = 1.17–2.28, p = 0.004; adjusted HR = 1.79, CI = 1.26–2.55, p = 0.001). Interestingly, 75% of events in the JANUS^® group occurred during the first 6 months after stent implantation. Similarly, the rate of clinically driven in-stent restenosis was higher in patients receiving JANUS^® stent (n = 10, 2%) compared to the CYPHER^® stent (n = 2, 4%). Concordantly, the relative risk for clinically driven in-stent restenosis was 81% higher in the JANUS^® group compared to the CYPHER^® group (crude HR = 1.81, 95% CI = 1.08–3.02, p = 0.02; adjusted HR = 2.24, CI = 1.26–3.96, p = 0.006).

Conclusion

The use of tacrolimus-eluting carbon coated JANUS^® stent was associated with worse clinical outcome compared to the sirolimus-eluting CYPHER^® stent in clinical routine use.

Lowe R, Menown IB, Nogareda G, Penn IM (2005) Coronary stents: in these days of climate change should all stents wear coats? Heart 91(Suppl 3):iii20–iii23CrossRefPubMed

Lau KW, Mak KH, Hung JS, Sigwart U (2004) Clinical impact of stent construction and design in percutaneous coronary intervention. Am Heart J 147(5):764–773CrossRefPubMed

Scheller B, Kuhler M, Cremers B, Mahnkopf D, Bohm M, Boxberger M (2008) Short- and long-term effects of a novel paclitaxel coated stent in the porcine coronary model. Clin Res Cardiol 97(2):118–123CrossRefPubMed

Wieneke H, Sawitowski T, Wnendt S, Fischer A, Dirsch O, Karoussos IA, Erbel R (2002) Stent coating: a new approach in interventional cardiology. Herz 27(6):518–526CrossRefPubMed

Cremers B, Biedermann M, Mahnkopf D, Bohm M, Scheller B (2009) Comparison of two different paclitaxel-coated balloon catheters in the porcine coronary restenosis model. Clin Res Cardiol 98(5):325–330CrossRefPubMed

Romagnoli E, Leone AM, Burzotta F, Trani C, Angeloni G, Materazzo G, Niccoli G, de Maria V, Perfetti M, Mazzari MA, Mongiardo R, Rebuzzi AG, Schiavoni G, Crea F (2008) Outcomes of the tacrolimus drug-eluting Janus stent: a prospective two-centre registry in high-risk patients. J Cardiovasc Med (Hagerstown) 9(6):94–589

Zahn R, Hamm CW, Zeymer U, Richardt G, Kelm M, Levenson B, Bonzel T, Tebbe U, Sabin G, Nienaber CA, Pfannebecker T, Senges J (2009) Coronary stenting with the sirolimus-eluting stent in patients with restenosis after intracoronary brachytherapy: results from the prospective multicentre German Cypher stent registry. Clin Res Cardiol 99:99–106CrossRefPubMed

Mollmann H, Elsasser A, Nef H, Schneider S, Nienaber CA, Richardt G, Weber M, Kelm M, Levenson B, Bonzel T, Tebbe U, Sabin G, Pfannebecker T, Senges J, Hamm CW (2008) Treatment of in-stent restenosis with sirolimus-eluting-stents: results from the prospective German Cypher stent registry. Clin Res Cardiol 97(7):432–440CrossRefPubMed

Bartorelli AL, Trabattoni D, Fabbiocchi F, Montorsi P, de Martini S, Calligaris G, Teruzzi G, Galli S, Ravagnani P (2003) Synergy of passive coating and targeted drug delivery: the tacrolimus-eluting Janus CarboStent. J Interv Cardiol 16(6):499–505CrossRefPubMed

10.

De Scheerder I, Szilard M, Yanming H, Ping XB, Verbeken E, Neerinck D, Demeyere E, Coppens W, Van de Werf F (2000) Evaluation of the biocompatibility of two new diamond-like stent coatings (Dylyn) in a porcine coronary stent model. J Invasive Cardiol 12(8):389–394PubMed

11.

Gutensohn K, Beythien C, Bau J, Fenner T, Grewe P, Koester R, Padmanaban K, Kuehnl P (2000) In vitro analyses of diamond-like carbon coated stents. Reduction of metal ion release, platelet activation, and thrombogenicity. Thromb Res 99(6):85–577CrossRef

12.

Linder S, Pinkowski W, Aepfelbacher M (2002) Adhesion, cytoskeletal architecture and activation status of primary human macrophages on a diamond-like carbon coated surface. Biomaterials 23(3):767–773CrossRefPubMed

13.

Antoniucci D, Bartorelli A, Valenti R, Montorsi P, Santoro GM, Fabbiocchi F, Bolognese L, Loaldi A, Trapani M, Trabattoni D, Moschi G, Galli S (2000) Clinical and angiographic outcome after coronary arterial stenting with the carbostent. Am J Cardiol 85(7):821–825CrossRefPubMed

14.

Antoniucci D, Valenti R, Migliorini A, Moschi G, Trapani M, Bolognese L, Santoro GM, Cerisano G (2001) Clinical and angiographic outcomes following elective implantation of the carbostent in patients at high risk of restenosis and target vessel failure. Catheter Cardiovasc Interv 54(4):420–426CrossRefPubMed

15.

Bartorelli AL, Trabattoni D, Montorsi P, Fabbiocchi F, Galli S, Ravagnani P, Grancini L, Cozzi S, Loaldi A (2002) Aspirin alone antiplatelet regimen after intracoronary placement of the Carbostent: the ANTARES study. Catheter Cardiovasc Interv 55(2):150–156CrossRefPubMed

16.

Airoldi F, Colombo A, Tavano D, Stankovic G, Klugmann S, Paolillo V, Bonizzoni E, Briguori C, Carlino M, Montorfano M, Liistro F, Castelli A, Ferrari A, Sgura F, Di Mario C (2004) Comparison of diamond-like carbon-coated stents versus uncoated stainless steel stents in coronary artery disease. Am J Cardiol 93(4):474–477CrossRefPubMed

17.

Haase J, Storger H, Hofmann M, Schwarz CE, Reinemer H, Schwarz F (2003) Comparison of stainless steel stents coated with turbostratic carbon and uncoated stents for percutaneous coronary interventions. J Invasive Cardiol 15(10):562–565PubMed

18.

Ong AT, Serruys PW, Aoki J, Hoye A, van Mieghem CA, Rodriguez-Granillo GA, Valgimigli M, Sonnenschein K, Regar E, van der Ent M, de Jaegere PP, McFadden EP, Sianos G, van der Giessen WJ, de Feyter PJ, van Domburg RT (2005) The unrestricted use of paclitaxel- versus sirolimus-eluting stents for coronary artery disease in an unselected population: one-year results of the taxus-stent evaluated at Rotterdam Cardiology Hospital (T-SEARCH) registry. J Am Coll Cardiol 45(7):1135–1141CrossRefPubMed

19.

Garcia-Tejada J, Gutierrez H, Albarran A, Hernandez F, Velazquez T, Rodriguez S, Gomez I, Tascon J (2007) Janus tacrolimus-eluting carbostent. Immediate and medium-term clinical results. Rev Esp Cardiol 60(2):197–200CrossRefPubMed

20.

Tamburino C, Di Salvo ME, Capodanno D, Capranzano P, Parisi R, Mirabella F, Scardaci F, Ussia G, Galassi AR, Fiscella D, Mehran R, Dangas G (2009) Real world safety and efficacy of the Janus tacrolimus-eluting stent: long-term clinical outcome and angiographic findings from the tacrolimus-eluting stent (TEST) registry. Catheter Cardiovasc Interv 73(2):243–248CrossRefPubMed

21.

Rinker A, Nusser T, Grossmann G, Koenig W, Wohrle J (2008) Angiographic results of a Tacrolimus-eluting stent in acute coronary syndrome lesions. Clin Res Cardiol 98(2):89–93CrossRefPubMed

22.

Trabattoni D, Antoniucci D, Fabbiocchi F, Valenti R, Montrosi P, Migliorini A (2003) First clinical experience with the tacrolimus-eluting Janus carbostent in de-novo coronary arteries: the JUPITER I study. Oral presentation at Transcatheter Cardiovascular Therapeutics 2003

23.

Morice M, Bestehorn HP, Carrie D, Macaya C, Aengevaeren W, Wijns W, Dubois C, De Winter R, Verheje S, Hoffmann S, Pachinger O, Di Mario C (2006) Direct stenting of de novo coronary stenoses with tacrolimus-eluting versus carbon-coated carbostent. The randomized Jupiter II trial. EuroInterv 2:45–52

24.

Han YL, Wang SL, Jing QM, Yu HB, Wang B, Ma YY, Luan B, Wang G (2007) Midterm outcomes of prospective, randomized, single-center study of the Janus tacrolimus-eluting stent for treatment of native coronary artery lesions. Chin Med J (Engl) 120(7):552–556

25.

Grines CL, Bonow RO, Casey DE Jr, Gardner TJ, Lockhart PB, Moliterno DJ, O’Gara P, Whitlow P (2007) Prevention of premature discontinuation of dual of antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College Physicians. J Am Coll Cardiol 49(6):734–739CrossRefPubMed

26.

Scheller B, Grandt A, Wnendt S, Lorenz G, Bohm M, Nickenig G (2005) Comparative study of tacrolimus and paclitaxel stent coating in the porcine coronary model. Z Kardiol 94(7):445–452CrossRefPubMed

27.

Bartorelli AL, Tamburino C, Trabattoni D, Galassi A, Serdoz R, Sheiban I, Piovaccari G, Zimarino M, Benassi A, Di Mario C, Sangiorgio P, Chierchia S, Reimers B (2007) Comparison of two antiplatelet regimens (aspirin alone versus aspirin + ticlopidine or clopidogrel) after intracoronary implantation of a carbofilm-coated stent. Am J Cardiol 99(8):1062–1066CrossRefPubMed

Title: Tacrolimus-eluting carbon-coated stents versus sirolimus-eluting stents for prevention of symptom-driven clinical end points
Authors: J. M. Siller-Matula
I. Tentzeris
B. Vogel
S. Schacherl
R. Jarai
A. Geppert
G. Unger
K. Huber
Publication date: 01-10-2010
Publisher: Springer-Verlag
Published in: Clinical Research in Cardiology / Issue 10/2010
Print ISSN: 1861-0684
Electronic ISSN: 1861-0692
DOI: https://doi.org/10.1007/s00392-010-0165-3

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Tacrolimus-eluting carbon-coated stents versus sirolimus-eluting stents for prevention of symptom-driven clinical end points

Abstract

Background

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 10/2010

GRACE risk score as predictor of in-hospital mortality in patients with chest pain

Cardiological evaluation after cerebral ischaemia

Management of percutaneous self-expanding bioprosthesis migration

Time to rheology in acute myocardial infarction: inflammation and erythrocyte aggregation as a consequence and not necessarily as precursors of the disease

Ivabradine in combination with beta-blocker therapy for the treatment of stable angina pectoris in every day clinical practice

Relationship between pulse transit time and blood pressure is impaired in patients with chronic heart failure